Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Posted by Stuart Ham on Jul 9th, 2026

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report)’s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.45 and traded as low as $3.43. Cryo-Cell International shares last traded at $3.43, with a volume of 4,183 shares.

Cryo-Cell International Stock Down 3.9%

The business’s 50 day moving average is $3.52 and its two-hundred day moving average is $3.45. The firm has a market cap of $27.65 million, a P/E ratio of -10.39 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $7.68 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International as of its most recent SEC filing. 10.44% of the stock is currently owned by institutional investors and hedge funds.

Cryo-Cell International Company Profile

(Get Free Report)

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.